ReviewProgress in retinal and eye research2017
Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma.
Review in Progress in retinal and eye research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 2 syntheses or guidelines pooled it, 199 citations in OpenAlex.
- Global mortality of glaucoma: a systematic review and meta-analysis of prospective studies.International ophthalmology · 2026Pooled it
- Changes in individuals' glaucoma progression velocity after IOP-lowering therapy: A systematic review.PloS one · 2025Pooled it
- A Topographical Analysis of Visual Field Improvement in a Phase 2 Randomized Trial of Nicotinamide and Pyruvate for Open-Angle Glaucoma.Investigative ophthalmology & visual science · 2026Trial
- Visual Field Pointwise Analysis of the Idiopathic Intracranial Hypertension Weight Trial (IIH:WT).Translational vision science & technology · 2023Trial
- Trial
- Long-term visual field progression after Ex-PRESS implantation versus trabeculectomy in refractory glaucoma.International ophthalmology · 2026Article
- Modeling variable interactions using Bayesian networks to identify direct predictors of radiation-induced optic neuropathy after proton therapy: implications for personalized toxicity risk stratification.Physics in medicine and biology · 2026Article
- Prophylactic self-assembled nucleic acid hydrogel targeting retinal ganglion cell cuproptosis and microglial neuroinflammation for retinal ischemia-reperfusion injury.Bioactive materials · 2026Article
- An Artificial Intelligence-Based Prognostic Model for Prediction of Functional Glaucoma Progression From Clinical and Structural Data.American journal of ophthalmology · 2026Article
- Intraoperative Visual Evoked Potential Monitoring in Endoscopic Endonasal Surgery for Nonpituitary Adenoma Suprasellar Tumors.Journal of clinical neurology (Seoul, Korea) · 2026Article
- Deep Learning-Based Prediction of Visual Field Mean Deviation from Numeric OCT Data in Glaucoma.Journal of imaging informatics in medicine · 2026Article
- GCIPL color coding on OCT predicts glaucoma conversion in normal-tension glaucoma suspects, including a high myopia subgroup.Scientific reports · 2026Article
- Article
- Translation and Validation of the Low Luminance Questionnaire in the Chinese Population.Translational vision science & technology · 2026Article
- Premium Intraocular Lenses and Their Impact on Visual Field Assessment: A Narrative Review.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Single-Cell Transcriptome Analysis of the Retina During the Development of Normal Tension Glaucoma in Mice.Inflammation · 2025Article
- Comparison of Methods for Visual Field Progression in Eyes With Central Visual Field Defects.Translational vision science & technology · 2025Article
- [Progression assessment of glaucoma].Die Ophthalmologie · 2025Review
- Two-Year Outcome of Selective Laser Trabeculoplasty for Normal-Tension Glaucoma in Japan: First-Line or Second-Line Selective Laser Trabeculoplasty (FSS) Study.Journal of clinical medicine · 2025Article
- Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Glaucomatous visual field progression has both personal and societal costs and therefore has a serious impact on quality of life. At the present time, intraocular pressure (IOP) is considered to be the most important modifiable risk factor for glaucoma onset and progression. Reduction of IOP has been repeatedly demonstrated to be an effective intervention across the spectrum of glaucoma, regardless of subtype or disease stage. In the setting of approval of IOP-lowering therapies, it is expected that effects on IOP will translate into benefits in long-term patient-reported outcomes. Nonetheless, the effect of these medications on IOP and their associated risks can be consistently and objectively measured. This helps to explain why regulatory approval of new therapies in glaucoma has historically used IOP as the outcome variable. Although all approved treatments for glaucoma involve IOP reduction, patients frequently continue to progress despite treatment. It would therefore be beneficial to develop treatments that preserve visual function through mechanisms other than lowering IOP. The United States Food and Drug Administration (FDA) has stated that they will accept a clinically meaningful definition of visual field progression using Glaucoma Change Probability criteria. Nonetheless, these criteria do not take into account the time (and hence, the speed) needed to reach significant change. In this paper we provide an analysis based on the existing literature to support the hypothesis that decreasing the rate of visual field progression by 30% in a trial lasting 12-18 months is clinically meaningful. We demonstrate that a 30% decrease in rate of visual field progression can be reliably projected to have a significant effect on health-related quality of life, as defined by validated instruments designed to measure that endpoint.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.